TLRY Tilray Brands, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
15:21
Apr 23
Apr 23
Reclassification huge opportunity for Tilray
The reclassification of cannabis from Schedule I to Schedule III in the US would allow Tilray to enter the US market for the first time. Tilray already has global infrastructure, grow capacity, brands, and medical research that can be transplanted quickly, creating a tremendous growth opportunity. Simon states they could be operational within six months of approval.
HIGH
22:13
Apr 22
Apr 22
Cannabis reclassification bullish for Tilray.
The Department of Justice is expected to reclassify cannabis to a less dangerous category, which would legitimize the industry, ease banking restrictions, and allow Tilray to bring its existing infrastructure, brands, and research to the U.S. market, potentially within six months, benefiting patients and the company's growth.
HIGH
19:38
Apr 22
Apr 22
Marijuana reclassification lowers taxes, spurs M&A.
The reclassification of marijuana to Schedule III will lower effective tax rates for U.S. cannabis companies from 41% to about 10%, spurring merger and acquisition activity in the sector, although it does not provide banking access or federal legalization.
HIGH
About TLRY Analyst Coverage
Buzzberg tracks TLRY (Tilray Brands, Inc.) across 1 sources. 3 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (100%). 3 total trade ideas tracked.